Sabet in Newsweek: Marijuana Rescheduling Is High-Risk, Low-Reward

As the Biden administration attempts to move full speed ahead in its efforts to loosen federal restrictions around marijuana, Americans should avail themselves of the opportunity to make their voices heard. Given the pot and tobacco industry’s long history of spreading misinformation and downplaying the harms associated with high-potency psychoactive THC drugs, we need to embrace the science and medical data as the nation faces a potential shift in policy.

Last month, following a process that strayed markedly from normal scientific and investigative procedures by the Department of Health and Human Services (HHS), the Drug Enforcement Administration (DEA) posted a proposed rule to the Federal Register summarizing the attempt to reschedule marijuana from Schedule I (the most restrictive level) to Schedule III. Schedule I drugs have a high potential for abuse and no accepted medical use, while Schedule III drugs have a lower potential for abuse and an accepted medical benefit.

Read the entire article HERE.